Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 126

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 126
---
| Legal, accounting, due diligence, travel and other expenses in connection with any business combination |     | $      |   150,000 |     |       13.6 | % |
| Directors and officers insurance premiums                                                               |     |        |   300,000 |     |       27.3 | % |
| Legal and accounting fees related to regulatory reporting obligations                                   |     |        |   125,000 |     |       11.4 | % |
| Payment for office space, administrative and support services                                           |     |        |   150,000 |     |       13.6 | % |
| Other miscellaneous expenses                                                                            |     |        |   375,000 |     |       34.1 | % |
| Total                                                                                                   |     | $      | 1,100,000 |     |      100.0 | % |

____________ (1)Includes amounts payable to public shareholders who properly redeem their shares in connection with our successful completion of our initial business combination. (2)A portion of the offering expenses have been paid from the proceeds of a loan from our sponsor of up to $1,850,000 as described in this prospectus. These loans will be repaid upon completion of this offering out of the $1,100,000 of offering proceeds that has been allocated for the payment of offering expenses (other than underwriting commissions) not held in the trust account. These expenses are estimates only. In the event that offering expenses are less than as set forth in this table, any such amounts will be used for post -closingworking capital expenses. In the event that the offering expenses are more than as set forth in this table, we may fund such excess with funds not held in the trust account. (3)The underwriters have agreed to defer underwriting commissions equal to 3.0% of the gross proceeds of this offering. Upon completion of our initial business combination, $6,000,000, which constitutes the underwriters’ deferred commissions (or up to $6,900,000 if the underwriters’ over -allotmentoption is exercised in full), of which 25.0% will be adjusted net of redemptions (i.e., for purposes of calculating the deferred underwriting commission net of redemptions, 25.0% of the deferred underwriting commissions will determined by the dollar amount that is product of (i) 3.0% multiplied by the product of the number of unre